IN8bio to Present at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference
IN8bio, a clinical-stage biopharmaceutical company specializing in gamma-delta T cell therapies, announced that its CEO and Co-founder, William Ho, will be participating in the H.C.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
IN8bio, a clinical-stage biopharmaceutical company specializing in gamma-delta T cell therapies, announced that its CEO and Co-founder, William Ho, will be participating in the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference.
The event is scheduled for June 25, 2024, at 2:30 p.m. ET. The presentation will include a fireside chat, providing insights into IN8bio's advancements and future plans.
A live webcast and replay of the presentation will be accessible under the 'Events and Presentations' section on the IN8bio website.
Details
News Market Reaction – INAB
The recorded move for INAB in the trading session of this news was -0.84%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW YORK, June 24, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, today announced that William Ho, CEO and Co-founder, will participate in a fireside chat during the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference on Tuesday, June 25, 2024 at 2:30 p.m. ET.
A live webcast and replay will be available under "Events and Presentations" in the News & Presentations section of the IN8bio website at https://investors.in8bio.com.
About IN8bio
IN8bio is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cell product candidates for solid and liquid tumors. Gamma-delta T cells are a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. IN8bio’s DeltEx platform employs allogenic, autologous, iPSC and genetically modified approaches to develop cell therapies, designed to effectively identify and eradicate tumor cells.
IN8bio has initiated a Phase 2 trial of INB-400 in GBM in the United States and has two ongoing Phase 1 trials in solid and hematologic tumors, including INB-200 for GBM and INB-100 for patients with hematologic malignancies, including acute myelogenous leukemia, undergoing haplo-matched bone marrow transplantation. IN8bio also has a broad portfolio of preclinical programs focused on addressing other hematological and solid tumor cancers. For more information visit www.IN8bio.com.
Company Contact
IN8bio, Inc.
Glenn Schulman, PharmD, MPH
+1 203.494.7411
gdschulman@IN8bio.com
Investors
Meru Advisors
Lee M. Stern
lstern@meruadvisors.com
Media Contact
Kimberly Ha
KKH Advisors
917-291-5744
Kimberly.ha@kkhadvisors.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.